Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to 66.76%.

  • Pulmonx's EBITDA Margin fell 1400.0% to 66.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.24%, marking a year-over-year increase of 90300.0%. This contributed to the annual value of 67.93% for FY2024, which is 191100.0% up from last year.
  • According to the latest figures from Q3 2025, Pulmonx's EBITDA Margin is 66.76%, which was down 1400.0% from 61.78% recorded in Q2 2025.
  • Over the past 5 years, Pulmonx's EBITDA Margin peaked at 57.21% during Q4 2024, and registered a low of 149.25% during Q1 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 84.4% (2023), whereas its average is 88.67%.
  • Examining YoY changes over the last 5 years, Pulmonx's EBITDA Margin showed a top increase of 2195800bps in 2021 and a maximum decrease of -584300bps in 2021.
  • Pulmonx's EBITDA Margin (Quarter) stood at 93.65% in 2021, then increased by 2bps to 91.44% in 2022, then grew by 25bps to 68.43% in 2023, then increased by 16bps to 57.21% in 2024, then fell by -17bps to 66.76% in 2025.
  • Its EBITDA Margin stands at 66.76% for Q3 2025, versus 61.78% for Q2 2025 and 63.71% for Q1 2025.